SAMSUNG BIOEPIS CO LTD
BiotechSAMSUNG BIOEPIS CO LTD is a biotechnology company focused on Immunology, Oncology, Gastroenterology.
SAMSUNG BIOEPIS CO LTD at a Glance
- Strong track record with 91% execution quality across 30 trials
- Fast trial execution (9 months median completion)
SAMSUNG BIOEPIS CO LTD's Key Drugs
SAMSUNG BIOEPIS CO LTD's core commercial portfolio centers on XBRYK, spanning Immunology and Oncology — its most strategically important drugs approved in the last 15 years.
SAMSUNG BIOEPIS CO LTD's Recent FDA Approvals
SAMSUNG BIOEPIS CO LTD secured 6 new FDA approvals for novel drugs (NDA/BLA) in the last two years.
SAMSUNG BIOEPIS CO LTD's Therapeutic Areas
SAMSUNG BIOEPIS CO LTD's approved drugs and pipeline span 4 therapeutic areas, led by Immunology and Oncology. Weighted by commercial stage — approved drugs count most, then late-stage trials.
SAMSUNG BIOEPIS CO LTD's Top Competitors
SAMSUNG BIOEPIS CO LTD's closest competitors by therapeutic-area and drug-target overlap include Novartis, AbbVie, and Johnson & Johnson. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
SAMSUNG BIOEPIS CO LTD Pipeline Snapshot
SAMSUNG BIOEPIS CO LTD has 16 active clinical programs from ClinicalTrials.gov — 9 Phase 3, 4 Phase 2 and 3 Phase 1.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • XBRYK leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Immunology pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Execution Intelligence
- • Phase 3: 10/11 completed
- • Speed: 9 months avg
Revenue forecasts • Trial milestones • Patent risk modeling
Active (0)
Discontinued (0)
Company Info
- First Approval
- 2017-04-21
- Latest
- 2026-04-29
- Applications
- 10
How We Calculate These Metrics
Execution Quality Score
Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.
What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Excellent (80%+): Top-tier execution, most trials reach planned endpoints
- Good (60-79%): Strong execution with occasional early terminations
- Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
- Needs Improvement (under 40%): High termination rates, execution challenges